GeneFerm Biotechnology Co. Ltd.

As of June 30, 2026, GeneFerm Biotechnology Co. Ltd. carries a market capitalization of 1.32B, placing it among publicly traded companies globally. Its enterprise value stands at 1.35B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, GeneFerm Biotechnology Co. Ltd. has 41.46M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, GeneFerm Biotechnology Co. Ltd. maintains a current ratio of 3.12, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, GeneFerm Biotechnology Co. Ltd. recorded 2.50M in income tax expense.

As of the close on October 22, 2026, GeneFerm Biotechnology Co. Ltd.'s stock has declined approximately 45.28% over the past 52 weeks. The 50-day moving average sits at 29.61, while the 200-day moving average is 36.42.

As of June 30, 2026, GeneFerm Biotechnology Co. Ltd. holds 281.97M in cash and equivalents against 312.78M in total debt, resulting in a net debt position of -59.65M. Total book value stands at 783.91M, with working capital of 398.82M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.